The illusion of evidence based medicineUploaded 26-03-22https://www.bmj.com/content/376/bmj.o702https://www.bmj.com/company/the-story-of-bmj-2/https://journals.bmj.com/homeEvidence based medicine has been corrupted bycorporate interests, failed regulation, and commercialisation of academia, argue these authorsJon Jureidini, research leaderhttps://www.adelaide.edu.au/directory/jon.jureidiniResearch Leader, child psychiatrist AdelaideLeemon B. McHenry, professor emeritusEmeritus Professor, Cal State UniversityNot commissioned, externally peer reviewedSolid scientific foundation for medicineValidity of this new paradigmReliable data from clinical trials,Mostly conducted by the pharmaceutical industryTHE JAPANESE JOURNAL OF ANTIBIOTICS74―1 61( 61 )http://jja-contents.wdc-jp.com/pdf/JJA74/74-1-open/74-1_44-95.pdfGlobal trends in clinical studies of ivermectin in COVID-19 Morimasa Yagisawa, Patrick J. Foster, Hideaki Hanaki, Satoshi ŌmuraKitasato University asked Merck and Co., Inc. to conduct clinical trials of ivermectin for COVID-19 in Japan. This company has priority to submit an application for an expansion of ivermectin’s indications, since the original approval for the manufacture and sale of ivermectin was conferred to it. However, the company said that it had no intention of conducting clinical trials. The release into the public domain of previously confidential pharmaceutical industry documents,valuable insight into the degree to which industry sponsored clinical trials are misrepresentedUntil this problem is corrected, evidence based medicine will remain an illusionKarl PopperCritical rationalism,advocated for the integrity of science and its role in an open, democratic societyA science of real integritypractitioners are careful not to cling to cherished hypotheses,and take seriously the outcome of the most stringent experimentsThis ideal is, however, threatened by corporations, financial interests trump the common goodMedicine is largely dominated by a small number of very large pharmaceutical companies,that compete for market share, but are effectively united in their efforts to expanding that market. Scientific progress is thwarted by the ownership of data and knowledge because industry suppresses negative trial results, fails to report adverse events, and does not share raw data with the academic research community. Patients die because of the adverse impact of commercial interests on the research agenda, universities, and regulators.Hierarchical power structures, product loyalty, and public relations propaganda over scientific integrity. Universities, have adopted a neo-liberal market approach, actively seeking pharmaceutical funding on commercial terms. As a result, university departments become instruments of industry: through company control of the research agenda,and ghostwriting of medical journal articles and continuing medical education, academics become agents for the promotion of commercial products.The corporate university also compromises the concept of academic leadership. Deans, (proper academics) have in places been replaced with fundraisers and academic managers, who are forced to demonstrate their profitability or show how they can attract corporate sponsors. In medicine, those who succeed in academia are likely to be key opinion leaders (KOLs in marketing parlance), whose careers can be advanced through the opportunities provided by industry,physicians are selected based on their influence on prescribing habits of other physiciansKOLs are sought out by industry for this influence and for the prestige that their university affiliation brings to the branding of the company’s products. KOLs present results of industry trials at medical conferences and in continuing medical education.I
Learn more about your ad choices. Visit megaphone.fm/adchoices
